Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Nasus Pharma Ltd. ( (NSRX) ).
On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup, Inc. to advance the development and commercialization of its intranasal Epinephrine program, NS002. This collaboration includes new agreements that replace previous ones, and it aims to leverage Aptar’s expertise in drug delivery systems to support NS002’s clinical development and regulatory submissions. The partnership provides Nasus with access to Aptar’s manufacturing capabilities, accelerating NS002’s path to market and reducing development risks. The agreements also include a supply arrangement for Aptar to exclusively provide the necessary delivery devices, contingent on FDA approval.
The most recent analyst rating on (NSRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products to treat emergency medical conditions. The company’s proprietary powder-based intranasal technology is designed for rapid and reliable drug delivery, offering needle-free alternatives for situations requiring quick absorption.
Average Trading Volume: 49,297
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.